X

Trial Profile

Intravenous Versus Intra-Arterial Fotemustine Chemotherapy in Patients With Liver Metastases From Uveal Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 04 Apr 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fotemustine (Primary) ; Fotemustine (Primary)
Indications Liver metastases; Uveal melanoma
Focus Therapeutic Use

Most Recent Events

02 Apr 2022 This trial has been completed in Italy, according to European Clinical Trials Database record.
07 Feb 2014 Results published in the Annals of Oncology.
12 Oct 2012 New source identified and integrated (European Clinical Trials Database; EudraCT2004-002245-12).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com